This Thursday (Nov 16), the National Health Surveillance Agency will decide whether or not to authorize the indication of Pfizer’s vaccine against covid-19 for children aged 5 to 11 years. Today, the immunizing agent can be applied to people from 12 years of age.
According to Anvisa, the pharmaceutical delivered the data and safety studies that support the application for approval of the vaccine’s indication for children. The request to expand the use of Pfizer’s vaccine for this age group was presented more than a month ago, on November 12th.
Analysis was carried out by technicians from the National Health Surveillance Agency and also by representatives of medical societies in the country. The conclusion will be presented today (16.Nov), in a virtual meeting.
If its use is approved, Anvisa can determine, for example, that the immunizing agent has a different bottle from the one currently used, to ensure sanitary safety. The version for children between 5 and 11 years old is less concentrated.
It is worth remembering that Pfizer was the first pharmaceutical company to obtain definitive registration for the vaccine against covid and it is one of the main ones in use in Brazil.
Butantan Institute
Yesterday (Dec 15), the Butantan Institute submitted a new request to Anvisa for authorization to indicate the CoronaVac vaccine for children and adolescents between 3 and 17 years old. It is the second time that the laboratory makes this type of request to the National Health Surveillance Agency. The first was denied due to lack of data.
Now, Anvisa has up to 30 days to reevaluate the Instituto Butantan’s request. Unlike Pfizer’s immunizing agent, CoronaVac vaccine is authorized for emergency use in Brazil for people 18 years of age or older.
